Muscle contraction

EMS is Transforming Conventional Fitness Training at SmartFit and its Franchises

Retrieved on: 
Wednesday, March 27, 2024
Health, Attention, Exercise, Risk, Research, Muscle fatigue, Muscle contraction, Electrode, Woman, Athlete, Injury, EMS, Rehabilitation, Dietary supplement

With celebrities like Liz Hurley, Heidi Klum, and Madonna endorsing its effectiveness, EMS training has piqued the curiosity of fitness enthusiasts worldwide, sparking a surge in interest and inquiries.

Key Points: 
  • With celebrities like Liz Hurley, Heidi Klum, and Madonna endorsing its effectiveness, EMS training has piqued the curiosity of fitness enthusiasts worldwide, sparking a surge in interest and inquiries.
  • Those utilizing EMS suits exhibited significant improvements in body circumference and cardiovascular function, hinting at the potential of EMS training to yield notable fitness gains.
  • Lara Oliveira, wife and mother of three children, spearheads SmartFit , the first EMS training fitness studio in Georgia, with a passion for revolutionizing the fitness landscape.
  • Inspired by her own struggles to juggle motherhood and fitness, Lara stumbled upon EMS training during a visit to her native Brazil in 2018.

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 22, 2024
Health, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Muscular dystrophy, Research, American Heart Association, Education, R9, MESA, Ageing, Fast Track, NSAA, McArdle, DUNE, Myopathy, Therapy, WMS, LYNX, ODD, Safety, Biomarker, Pharmacokinetics, HCM, Clinical trial, Caregiver, FOX, FDA, Muscle contraction, Engagement, Duchenne muscular dystrophy, ARCH, Administration, Patient, Disease, Pharmaceutical industry

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2023 and recent business highlights.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2023 and recent business highlights.
  • “In 2023, we made tremendous progress advancing our novel muscle-targeted therapeutics in the clinic,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise.
  • Research and development (R&D) expenses were $27.7 million for the fourth quarter of 2023, compared to $23.8 million for the immediately preceding quarter.
  • General and Administrative (G&A) expenses were $6.2 million for the fourth quarter of 2023, compared to $5.7 million for the immediately preceding quarter.

Curious Kids: why do we shiver when we feel cold?

Retrieved on: 
Monday, February 12, 2024
Woman, Hypothermia, Nervous system, Muscle contraction, Temperature, Thermoregulation, Mammal, Skeletal muscle, Bed, Heart, Shivering, Movement, Brain, Running

“Why do we shiver when we feel cold?” – Syeda, age 10, from Karachi

Key Points: 
  • “Why do we shiver when we feel cold?” – Syeda, age 10, from Karachi
    What a cool question, Syeda!
  • If our body temperature drops too low, our heart, nervous system and other organs are not able to work normally.
  • All mammals have the ability to shiver, so your pet cat or dog might shiver when they’re cold too.
  • Read more: Curious Kids: if our bodies are happy at 37℃, why do we feel so unhappy when it's too hot outside?

Nathaniel A. Dyment, PhD, Presented With 2024 Kappa Delta Young Investigator Award for Research on Formation, Maintenance and Repair of Tendons and Ligaments

Retrieved on: 
Friday, February 2, 2024
Growth, Cell, Embryo, Research, Element, Muscle contraction, Achilles tendon, Injury, Homeostasis, University of Pennsylvania, Anterior cruciate ligament reconstruction, Fibrocartilage, Ligament, DSM-IV codes, DRS, Tissue, Tendon, Doctor of Philosophy, University, Tonia, Medical imaging

The award recognizes outstanding clinical research related to musculoskeletal disease or injury by investigators under 40 years old.

Key Points: 
  • The award recognizes outstanding clinical research related to musculoskeletal disease or injury by investigators under 40 years old.
  • Unfortunately, clinicians and researchers lack biological benchmarks to assess the repairs of these tissues, hampering the development of new therapies.
  • "Therefore, the development of treatments to successfully repair or regenerate tendons is very difficult.
  • The degeneration that is happening in tendons can take decades to develop, making successful treatment of these injuries a big challenge.

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

Retrieved on: 
Monday, January 29, 2024
Hope, Development, Woman, Medical Research Council, Patient, NINDS, Fatigue, CRADA, Intramural sports, Ryanodine receptor 1, Journal, Muscle contraction, Safety, Disease, Muscle weakness, NIH, DSM-IV codes, RYR1, Publication, Research, Bangladesh Technical Education Board, Pharmacokinetics, Pharmaceutical industry

The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).

Key Points: 
  • The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).
  • These results warrant further development of ARM210 as a potential disease modifying treatment for RYR1-RM in a randomized, placebo-controlled Phase 2 trial.
  • We look forward to the next stages in the development of this important drug.”
    Further information about this Phase 1b trial can be found online at: https://clinicaltrials.gov/study/NCT04141670 .
  • Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial, Todd et al, eClinicalMedicine https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00012-9/fulltext

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

Retrieved on: 
Monday, January 29, 2024
Hope, Development, Woman, Medical Research Council, Patient, NINDS, Fatigue, CRADA, Intramural sports, Ryanodine receptor 1, Journal, Muscle contraction, Safety, Disease, Muscle weakness, NIH, DSM-IV codes, RYR1, Publication, Research, Bangladesh Technical Education Board, Pharmacokinetics, Pharmaceutical industry

The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).

Key Points: 
  • The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).
  • These results warrant further development of ARM210 as a potential disease modifying treatment for RYR1-RM in a randomized, placebo-controlled Phase 2 trial.
  • We look forward to the next stages in the development of this important drug.”
    Further information about this Phase 1b trial can be found online at: https://clinicaltrials.gov/study/NCT04141670 .
  • Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial, Todd et al, eClinicalMedicine https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00012-9/fulltext

Human medicines European public assessment report (EPAR): Nuceiva, botulinum toxin type a, Date of authorisation: 27/09/2019, Revision: 6, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, INN, Constipation, Infection, Allergy, Forehead, ATC, Antibody, Depression, International, Skin, Injection, Headache, Eyelid, Lambert–Eaton myasthenic syndrome, Language, Ageing, Muscle weakness, Inflammation, Eyebrow, Hypersensitivity, Anxiety, Muscle contraction, Clostridium botulinum, European Medicines Agency, Myasthenia gravis, Acetylcholine, Select, Patient, Safety, Anatomy, GLS, Disorder, IIA, Medical device

Human medicines European public assessment report (EPAR): Nuceiva, botulinum toxin type a, Date of authorisation: 27/09/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nuceiva, botulinum toxin type a, Date of authorisation: 27/09/2019, Revision: 6, Status: Authorised

Myocene signs contract with OGC Nice for muscle fatigue measurement technology

Retrieved on: 
Tuesday, November 21, 2023
School, Injury, Partnership, Ruhr University Bochum, Football, University, Muscle fatigue, Health, Fatigue, Outline of health sciences, Basketball, Rest, Perception, Jean Monnet University, RC Strasbourg Alsace, Muscle contraction, S.C. Braga, HES-SO, Volleyball, CEP, US Ivry, OGC Nice

LIÈGE, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Myocene, the company developing a cutting-edge device for measuring muscle fatigue1, today announces that it has signed a contract to supply its patented technology to the French professional football club OGC Nice. The financial terms of the agreement have not been disclosed.

Key Points: 
  • The top-flight club in France’s Ligue 1 will use Myocene’s technology during training sessions and matches to optimize players' performance.
  • Muscle fatigue measurements will be taken each week throughout the season to assess players’ recovery levels, and their general condition after each match.
  • “We chose Myocene’s device as a tool that allows us to reliably assess the players' 'freshness' and recovery levels,” explained Laurent Bessiere, performance director at OGC Nice.
  • Myocene’s innovative technology can calculate an individual’s exact muscle fatigue index in just two minutes.

Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
MMN, Muscle contraction, Therapy, Multifocal motor neuropathy, Investment, Disease, Risk, Form, Magenta, GMG, Patient, Complement component 1s, Research, CIDP, Bacteria, Half-life, Infection, Dianthus, YTE, Vaccine, Pharmaceutical industry, Airline, Cryptocurrency

Top-line Phase 1 data across seven single and multiple ascending dose cohorts with 52 healthy volunteers establish DNTH103’s best-in-class potential.

Key Points: 
  • Top-line Phase 1 data across seven single and multiple ascending dose cohorts with 52 healthy volunteers establish DNTH103’s best-in-class potential.
  • Research and development expenses for the quarter ended September 30, 2023 were $8.0 million, inclusive of $0.4 million of stock-based compensation.
  • Net loss for the quarter ended September 30, 2023 was $14.8 million or $3.78 net loss per share (basic and diluted).
  • For additional information on the Company’s financial results for the quarter ended September 30, 2023, please refer to the Form 10-Q filed with the SEC.

Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health, Pharmaceutical, Physical Therapy, Cardiology, LYNX, Research, FOX, DUNE, Ageing, Education, Biomarker, Muscular dystrophy, Muscular Dystrophy Association, NSAA, G&A, Myopathy, Glycogen storage disease type V, American Heart Association, WMS, R, Muscle contraction, Pharmacokinetics, Dystrophinopathy, Disorder, Glycogen, PK, Clinical trial, Duchenne muscular dystrophy, McArdle, Safety, HCM, Therapy, Patient, MESA, R9, Administration, Pharmaceutical industry, Edgewise, Duchenne, Becker

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2023 and recent business highlights.

Key Points: 
  • Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2023 and recent business highlights.
  • “I’m thrilled with the progress we’ve made in 2023 across our skeletal and cardiovascular programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise.
  • Research and development (R&D) expenses were $23.8 million for the third quarter of 2023, compared to $19.6 million for the immediately preceding quarter.
  • General and Administrative (G&A) expenses were $5.7 million for the third quarter of 2023, compared to $5.8 million for the immediately preceding quarter.